297 related articles for article (PubMed ID: 24974155)
1. Corticosteroid treatment for community-acquired pneumonia--the STEP trial: study protocol for a randomized controlled trial.
Blum CA; Nigro N; Winzeler B; Suter-Widmer I; Schuetz P; Briel M; Bingisser R; Zimmerli W; Ullmer E; Elsaesser H; Tarr P; Wirz S; Thomann R; Hofmann E; Rodondi N; Duplain H; Burki D; Mueller B; Christ-Crain M
Trials; 2014 Jun; 15():257. PubMed ID: 24974155
[TBL] [Abstract][Full Text] [Related]
2. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial.
Blum CA; Nigro N; Briel M; Schuetz P; Ullmer E; Suter-Widmer I; Winzeler B; Bingisser R; Elsaesser H; Drozdov D; Arici B; Urwyler SA; Refardt J; Tarr P; Wirz S; Thomann R; Baumgartner C; Duplain H; Burki D; Zimmerli W; Rodondi N; Mueller B; Christ-Crain M
Lancet; 2015 Apr; 385(9977):1511-8. PubMed ID: 25608756
[TBL] [Abstract][Full Text] [Related]
3. Benefit of adjunct corticosteroids for community-acquired pneumonia in diabetic patients.
Popovic M; Blum CA; Nigro N; Mueller B; Schuetz P; Christ-Crain M
Diabetologia; 2016 Dec; 59(12):2552-2560. PubMed ID: 27614658
[TBL] [Abstract][Full Text] [Related]
4. Adjunct prednisone in community-acquired pneumonia: 180-day outcome of a multicentre, double-blind, randomized, placebo-controlled trial.
Blum CA; Roethlisberger EA; Cesana-Nigro N; Winzeler B; Rodondi N; Blum MR; Briel M; Mueller B; Christ-Crain M; Schuetz P
BMC Pulm Med; 2023 Dec; 23(1):500. PubMed ID: 38082273
[TBL] [Abstract][Full Text] [Related]
5. Hydrocortisone plus fludrocortisone for community acquired pneumonia-related septic shock: a subgroup analysis of the APROCCHSS phase 3 randomised trial.
Heming N; Renault A; Kuperminc E; Brun-Buisson C; Megarbane B; Quenot JP; Siami S; Cariou A; Forceville X; Schwebel C; Leone M; Timsit JF; Misset B; Benali MA; Colin G; Souweine B; Asehnoune K; Mercier E; Chimot L; Charpentier C; François B; Boulain T; Petitpas F; Constantin JM; Dhonneur G; Baudin F; Combes A; Bohé J; Loriferne JF; Cook F; Slama M; Leroy O; Capellier G; Dargent A; Hissem T; Bounab R; Maxime V; Moine P; Bellissant E; Annane D; ;
Lancet Respir Med; 2024 May; 12(5):366-374. PubMed ID: 38310918
[TBL] [Abstract][Full Text] [Related]
6. Steroid therapy and outcome of parapneumonic pleural effusions (STOPPE): Study protocol for a multicenter, double-blinded, placebo-controlled randomized clinical trial.
Fitzgerald DB; Waterer GW; Read CA; Fysh ET; Shrestha R; Stanley C; Muruganandan S; Lan NSH; Popowicz ND; Peddle-McIntyre CJ; Rahman NM; Gan SK; Murray K; Lee YCG
Medicine (Baltimore); 2019 Oct; 98(43):e17397. PubMed ID: 31651842
[TBL] [Abstract][Full Text] [Related]
7. Can an antimicrobial stewardship program reduce length of stay of immune-competent adult patients admitted to hospital with diagnosis of community-acquired pneumonia? Study protocol for pragmatic controlled non-randomized clinical study.
DiDiodato G; McArthur L; Beyene J; Smieja M; Thabane L
Trials; 2015 Aug; 16():355. PubMed ID: 26272324
[TBL] [Abstract][Full Text] [Related]
8. Adjunctive Systemic Corticosteroids for Hospitalized Community-Acquired Pneumonia: Systematic Review and Meta-Analysis 2015 Update.
Horita N; Otsuka T; Haranaga S; Namkoong H; Miki M; Miyashita N; Higa F; Takahashi H; Yoshida M; Kohno S; Kaneko T
Sci Rep; 2015 Sep; 5():14061. PubMed ID: 26374694
[TBL] [Abstract][Full Text] [Related]
9. Simvastatin to modify neutrophil function in older patients with septic pneumonia (SNOOPI): study protocol for a randomised placebo-controlled trial.
Greenwood H; Patel J; Mahida R; Wang Q; Parekh D; Dancer RC; Khiroya H; Sapey E; Thickett DR
Trials; 2014 Aug; 15():332. PubMed ID: 25146127
[TBL] [Abstract][Full Text] [Related]
10. Corticosteroids as adjunctive treatment in community-acquired pneumonia.
Sibila O; Ferrer M; Agustí C; Torres A
Minerva Anestesiol; 2014 Dec; 80(12):1336-44. PubMed ID: 24518215
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization.
Mikami K; Suzuki M; Kitagawa H; Kawakami M; Hirota N; Yamaguchi H; Narumoto O; Kichikawa Y; Kawai M; Tashimo H; Arai H; Horiuchi T; Sakamoto Y
Lung; 2007; 185(5):249-255. PubMed ID: 17710485
[TBL] [Abstract][Full Text] [Related]
12. Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia.
Wirz SA; Blum CA; Schuetz P; Albrich WC; Noppen C; Mueller B; Christ-Crain M; Tarr PE;
Eur Respir J; 2016 Oct; 48(4):1150-1159. PubMed ID: 27471201
[TBL] [Abstract][Full Text] [Related]
13. Reduction of corticosteroid use in outpatient treatment of exacerbated COPD - Study protocol for a randomized, double-blind, non-inferiority study, (The RECUT-trial).
Urwyler P; Boesing M; Abig K; Cattaneo M; Dieterle T; Zeller A; Bachler H; Markun S; Senn O; Merlo C; Essig S; Ullmer E; Rutishauser J; Schuurmans MM; Leuppi JD
Trials; 2019 Dec; 20(1):727. PubMed ID: 31842993
[TBL] [Abstract][Full Text] [Related]
14. The IMPROVE-GAP Trial aiming to improve evidence-based management of community-acquired pneumonia: study protocol for a stepped-wedge randomised controlled trial.
Skinner EH; Lloyd M; Janus E; Ong ML; Karahalios A; Haines TP; Kelly AM; Shackell M; Karunajeewa H
Trials; 2018 Feb; 19(1):88. PubMed ID: 29402313
[TBL] [Abstract][Full Text] [Related]
15. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial.
Torres A; Sibila O; Ferrer M; Polverino E; Menendez R; Mensa J; Gabarrús A; Sellarés J; Restrepo MI; Anzueto A; Niederman MS; Agustí C
JAMA; 2015 Feb; 313(7):677-86. PubMed ID: 25688779
[TBL] [Abstract][Full Text] [Related]
16. Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial.
Ceccato A; Cilloniz C; Ranzani OT; Menendez R; Agusti C; Gabarrus A; Ferrer M; Sibila O; Niederman MS; Torres A
PLoS One; 2017; 12(6):e0178022. PubMed ID: 28617807
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in hospitalized community-acquired pneumonia: a retrospective study of a prospective observational cohort.
Ito A; Ishida T; Tokumasu H; Washio Y; Yamazaki A; Ito Y; Tachibana H
BMC Pulm Med; 2017 May; 17(1):78. PubMed ID: 28464807
[TBL] [Abstract][Full Text] [Related]
18. Corticosteroids for pneumonia.
Stern A; Skalsky K; Avni T; Carrara E; Leibovici L; Paul M
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD007720. PubMed ID: 29236286
[TBL] [Abstract][Full Text] [Related]
19. [Corticosteroids in community acquired pneumonia: Where are we in 2018?].
Soumagne T; Rabbat A
Rev Mal Respir; 2018 Oct; 35(8):813-827. PubMed ID: 30217573
[TBL] [Abstract][Full Text] [Related]
20. Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial.
Uranga A; España PP; Bilbao A; Quintana JM; Arriaga I; Intxausti M; Lobo JL; Tomás L; Camino J; Nuñez J; Capelastegui A
JAMA Intern Med; 2016 Sep; 176(9):1257-65. PubMed ID: 27455166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
